Scientific data supports beneficial effects of Pivotal\'s Omega-3 formulation
Vascazen was shown to cause the most pronounced increase in blood flow in University of Strasbourg study
Pivotal Therapeutics, a Canadian specialist pharmaceutical company with a focus on Omega-3 therapies, has reported the positive findings of research into its Vascazen product, which is currently available in the US as a prescription-only medical food formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients.
The study, carried out by researchers at the University of Strasbourg, France, published in the scientific journal PLOS ONE, demonstrated that the sustained endothelial vasodilatory effect of Omega-3 formulations are EPA:DHA ratio and purity dependent and involve predominantly the endothelial nitric oxide synthase derived nitric oxide formation.
Pivotal's 6:1 EPA:DHA formulation of Vascazen was shown to cause the most pronounced increase in blood flow when compared with a 1:1 EPA:DHA, pure EPA or pure DHA, the study found.
The study is said to be the first to demonstrate that the biological activity of Omega-3 formulations is not linked to either the ratio or the purity alone but depends on the interplay of the components of each respective formulation.
'The significance of these results emphasises not only the superior sustained endothelial vasodilatory profile of Pivotal's Vascazen, but also points to its beneficial effects in Omega-3 deficient individuals,' said George Jackowski, Chief Scientific Officer at Pivotal.
'We are very excited that the Vascazen formulation was superior to the other existing commercial products in the marketplace in terms of sustained coronary vasodilation (i.e. increase of blood flow), which is important for patients with Coronary Heart Disease who have compromised coronary vessels.'
